VC-backed Aligos Therapeutics goes public

Aligos Therapeutics, a biopharmaceutical company focused on treating viral infections and liver diseases, has raised about $150 million for its IPO after pricing its 10 million shares at $15 per share.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this